Core Scientific, Inc. current report, 27 February 2023

Vollständiges Dokument

Core Scientific, Inc. Form 8-K Summary

Business Context and Reporting Period

The report concerns events beginning February 27, 2023, during Core Scientific’s Chapter 11 bankruptcy proceedings. The company and certain affiliates filed voluntary Chapter 11 petitions on December 21, 2022 and continue operating as debtors-in-possession under Bankruptcy Court supervision. The report was signed March 2, 2023.

Material Financing and Key Terms

  • On February 27, 2023, the debtors entered into a Senior Secured Super-Priority Replacement Debtor-in-Possession Loan and Security Agreement with B. Riley Commercial Capital, LLC as administrative agent.
  • The Replacement DIP Facility provides a non-amortizing, super-priority senior secured term loan facility of up to $70 million.
  • $35 million was available under the interim Bankruptcy Court order, with the remaining $35 million available after entry of the final order on March 1, 2023.
  • Interest accrues at 10% per year and is payable in kind in arrears on the first day of each calendar month.
  • The administrative agent received an upfront payment equal to 3.5% of total commitments, payable in kind.
  • Lenders are entitled to a cash exit premium equal to 5% of the amount of loans repaid, reduced, or satisfied.
  • The stated maturity date is December 22, 2023, with a potential three-month extension to March 22, 2024, subject to specified conditions.

Material Changes, Outlook, and Risks

  • The financing replaces or supplements post-petition financing authorized in connection with the Chapter 11 cases and creates a new direct financial obligation under Item 2.03.
  • The facility is subject to representations, warranties, covenants, and events of default. Following an event of default, the administrative agent may reduce remaining commitments and accelerate outstanding obligations.
  • The facility terminates upon the earliest of the effective date of a Chapter 11 plan, consummation of certain asset sales, acceleration and termination of commitments, or conversion of the bankruptcy cases to Chapter 7.
  • The filing provides no revenue, profit, cash-flow, margin, operating-performance, or liquidity metrics for the reporting period.
  • Core Scientific’s common stock and warrants began trading exclusively on the OTC Pink Marketplace on January 3, 2023 under the symbols CORZQ and CRZWQ, respectively.

Most Important Facts to Verify

  • Whether the full $70 million Replacement DIP Facility was drawn and the amount of accrued payment-in-kind interest.
  • The final Bankruptcy Court order and any conditions, milestones, or restrictions imposed on the financing.
  • Current cash balances, operating liquidity, and compliance with DIP covenants and reporting requirements.
  • The status and expected timing of the Chapter 11 plan, potential asset sales, or other restructuring outcomes.
  • The complete Replacement DIP Credit Agreement filed as Exhibit 10.1, including collateral, default provisions, borrowing conditions, and extension requirements.